Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Laos’ first Pint of Science: warty newts, COVID, AI for Instagram, and more!

LOMWRU MORU

Organised by a grass-root community of thousands of scientists across the world, Pint of Science 2022 allowed researchers in 25 countries and over 800 cities to share their latest findings with lay folk in interesting, informal settings. Lao PDR joined the global Pint of Science family on Monday 9 May, when the first-ever Pint of Science Laos kicked off!

Modelling the Cost-Effectiveness of COVID-19 Vaccination Strategies in Kenya

KWTRP

The KEMRI-Wellcome Trust Research Programme today released the results of its latest modelling on COVID-19 vaccine scale-up within the country. The analysis found that the country’s COVID-19 vaccination campaign can achieve greater value for money if it focuses on the elderly, rather than a strategy that pursues scaling up vaccines to the whole population.

Indian authorities sign an MoU for a data and skill-sharing partnership between ICMR and IDDO

OCGHR

The Indian government’s Union Cabinet, chaired by Prime Minister Shri Narendra Modi, has approved a Memorandum of Understanding (MoU) between the Indian Council of Medical Research (ICMR) and the Infectious Diseases Data Observatory (IDDO), based at the University of Oxford.

Picturing Health: The Burden of Leprosy in Eastern Indonesia

EOCRU OUCRU

The Eijkman Oxford Clinical Research Unit in Indonesia and Sumba Foundation collaborated with photographer Yoppy Pieter to express the human face of leprosy in Sumba, a remote island in eastern Indonesia. The project aimed to visualize the story of leprosy and raise awareness of this debilitating and heavily stigmatised disease

Patient recruitment on track in Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa

MORU

Today is World Malaria Day. The global fight against malaria is at a critical point. No new antimalarial drugs are expected in the near future, and if multi-drug resistant falciparum malaria becomes established in East Africa and spreads to other parts of Africa, millions will be at risk of drug-resistant malaria infection and death. The development of triple artemisinin-based combination therapies aims to prevent or delay the emergence of artemisinin and multi-drug resistant malaria in Africa.

PRIORITISE study team publishes results, now seeks partners

COMRU MORU

In regions where few people have received Covid-19 vaccines, health systems remain vulnerable to surges in SARS-CoV-2 infections. During the delta-wave of COVID-19 in India, for example, healthcare facilities and staff across the country struggled to cope with the surge in the number of cases of COVID-19 due to a shortage of hospital beds for people with severe cases, plus shortages of medicines and limited human resources.

Emelda Okiro awarded Wellcome Senior Research Fellowship

KWTRP

Dr Emelda Okiro has been awarded the prestigious Wellcome Senior Research Fellowship. Emelda’s fellowship is the first African Senior Research Fellowship awarded in the KEMRI-Wellcome Research Programme and among the less than five SRFs awarded to researchers in Africa.

Large African and South Asian research network finds half of deaths among children admitted to hospital happens after discharge

KWTRP

Young children in sub-Saharan Africa and South Asia who become sick or malnourished continue to have a high risk of death in the six months after being hospitalized, according to findings by researchers in the Childhood Acute Illness & Nutrition (CHAIN) Network. Appearing in The Lancet Global Health, the study of 3,101 acutely ill children at nine hospitals in six countries across sub-Saharan Africa and South Asia found that 48% of the 350 deaths recorded occurred within six months after discharge from hospital.

Research Culture at OUCRU

EOCRU OUCRU

What do we mean by 'Research Culture' and how has fostering a multinational, collaborative culture helped us deliver world-class research? Let's explore the research culture at OUCRU.

The GRAM Project has moved

OCGHR

The Global Research on Antimicrobial Resistance (GRAM) Project has a new centre of operations at the University of Oxford, after moving this month from the Big Data Institute to the Centre for Tropical Medicine and Global Health, under the leadership of Dr. Benn Sartorius (PI) and Prof. Christiane Dolecek (co-PI).

Sharing expertise with scientific collaborators in India

OCGHR

The Indian Council for Medical Research (ICMR) National Institute of Malaria Research (NIMR) and IDDO collaborate on a joint capacity building venture to train young researchers across three infectious diseases: malaria, visceral leishmaniasis and lymphatic filariasis

Community and Public Engagement at KWTRP

Public Engagement

Monitoring and Evaluation helps us keep track of our public engagement activities and outcomes. KEMRI -Wellcome Trust recently completed a report detailing our experiences and learning.

Artemisinin combination therapy trials need longer follow-up to detect late treatment failures for Plasmodium falciparum malaria

OCGHR

WWARN researchers have been assessing the recommended minimum follow-up period in capturing polymerase chain reaction (PCR)-confirmed recrudescence following treatment with fixed-dose artemisinin combination therapies (ACTs) for patients with uncomplicated Plasmodium falciparum malaria.

Paxlovid to be investigated by the RECOVERY Trial as a potential treatment for patients hospitalised with COVID-19

OCGHR

The RECOVERY Trial begins testing the antiviral treatment Paxlovid. Paxlovid, an oral antiviral treatment developed by Pfizer, is a combination of nirmatrelvir and ritonavir. Nirmatrelvir inhibits an enzyme that is critical for the replication of the virus that causes COVID-19, whilst ritonavir increases the concentration of nirmatrelvir.

Policy and Public Engagement at OUCRU

Public Engagement

Why does OUCRU place an important focus on engaging with its important partners, policy makers, the press, the community, and young people? Explore our work in policy & public engagement.

The RECOVERY Trial - two years on

OCGHR

One trial. Over 47,000 participants. Nearly 200 hospital sites, across six countries. Ten results. Four effective COVID-19 treatments. And behind them all, an army of countless researchers, doctors, nurses, statisticians and supporting staff.

World TB Day 2022: Invest to End TB. Save Lives

OUCRU

Each year on 24 March, World TB Day is commemorated to raise awareness of this devastating and deadly disease. The theme for this year’s World TB Day is “Invest to End TB. Save Lives”, conveying the urgent need to invest resources to ramp up the fight against TB and achieve the commitments to end TB made by global leaders.

Under the Mask, drama film based on testimonies of tuberculosis patients

MORU Public Engagement SMRU

In 2022, tuberculosis (TB) remains a major global health problem, particularly in developing countries. On the Thai-Myanmar border, TB is an important problem among migrants, a vulnerable, very mobile population, with unstable, often difficult living conditions, insecure incomes, and poor access to health services.

TACT-CV study shows artemether–lumefantrine plus amodiaquine an effective treatment for multidrug-resistant malaria in GMS

MORU OUCRU

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.

OUCRU Research Themes and Future

EOCRU OUCRU Video

In this video, explore OUCRU's research areas and what questions we are aiming to answer in the next 5 years.

RECOVERY Trial launches in Ghana

OCGHR

The world’s largest clinical trial investigating treatments for COVID-19 has now launched in Ghana, West Africa. This is the sixth country to take part in RECOVERY, joining Indonesia, Nepal, South Africa, Vietnam, and the United Kingdom.

Covid-19 at OUCRU - Research and engagement portfolio

EOCRU OUCRU OUCRU-Nepal

In the last two years, OUCRU has worked with our partners and collaborators to conduct various research and engagement projects in response to the COVID-19 pandemic. This portfolio provides an overview of all the on-going projects that our entire programme have been working on to contribute to the understanding and management of COVID-19 and its national, regional and global impact.

OUCRU Tour - Ho Chi Minh City, Hanoi (Vietnam) and Jakarta (Indonesia)

EOCRU OUCRU

Are you curious about what a leading regional research hub for infectious disease look like? OUCRU is a large-scale research programme with offices in Ho Chi Minh City, Hanoi (Vietnam) and Jakarta (Indonesia). In this video, our leading scientists will take you on a tour of OUCRU's facilities and introduce you to our host institutions: the Hospital for Tropical Diseases (Ho Chi Minh City, Vietnam), the National Hospital for Tropical Diseases (Hanoi, Vietnam), and the Eijkman Institute (Jakarta, Indonesia)

Oral paratyphoid vaccine to begin human trials

OCGHR

The University of Oxford in collaboration with the University of Maryland School of Medicine has begun recruiting for a Phase I/II trial of a new paratyphoid vaccine in human volunteers in Oxford. In the first study of its kind, after vaccination volunteers will be 'challenged' with paratyphoid to see whether the vaccine can prevent infection.

Largest-ever IPD meta-analysis of malaria patients to inform haemoglobin changes

OCGHR

A new malaria study using a very large analysis of pooled individual patient data (IPD) from more than 70,000 patients of all ages, has been published in BMC Medicine by the WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group

From Vietnam to the World - 30 Years of OUCRU

EOCRU OUCRU OUCRU-Nepal

After over 30 years of working in infectious disease in Vietnam, Indonesia, and Nepal, OUCRU has developed and established its foothold as a crucial regional research hub in infectious diseases, bridging the gap between research and treatments all over the world. What have we done? How did we do it? And what will OUCRU continue to focus on in the next 5 years?

New RECOVERY trial result: baricitinib reduces deaths in patients hospitalised with COVID-19

OCGHR

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that baricitinib, an anti-inflammatory drug normally used to treat rheumatoid arthritis, reduces the risk of death when given to hospitalised patients with severe COVID-19. The benefit was in addition to those of dexamethasone and tocilizumab, two other anti-inflammatory treatments which have previously been shown to reduce the risk of death in these patients.

The University of Oxford annouces the new Pandemic Sciences Institute

OCGHR Video

The University of Oxford has launched a new institute of global research collaboration and excellence, the Pandemic Sciences Institute. It will harness the strong global research collaborations that the University of Oxford has developed over more than forty years to ensure that the world is better equipped to create global and equitable science-driven solutions to prepare for, identify, and counter future pandemic threats.

OUCRU-Vietnam launches new mental health resource: “Caring for Mental Health and Wellbeing”

OUCRU

OUCRU Public and Community Engagement Department has compiled a directory of services for Vietnamese communities and people living in Vietnam. Throughout the Covid-19 pandemic, OUCRU has been actively involved in Covid-19 diagnostics, treatment, research, health education, and community engagement. We have worked in collaboration with the Vietnamese Ministry of Health and respected medical and research institutes across Vietnam.

Training Programme in Modelling for Global Health

OCGHR

Starting October 2022 and based on the MSc in Modelling for Global Health, our new Training Programme in Modelling for Global Health allows participants to select a bespoke set of short courses from the Modelling for Global Health curriculum.

OUCRU and Dragon Capital Group announce partnership on intensive care development programme

OUCRU

Oxford University Clinical Research Unit (OUCRU), a leading clinical and public health research unit, and Dragon Capital Group, an established financial institution focused on Vietnam and other Southeast Asian emerging markets, announced a two-year partnership to support the development of high-quality intensive care for those with life-threatening infectious diseases in Vietnam.

Trial of holographic communication in Centre for Tropical Medicine & Global Health – an Enterprise....

OCGHR

From 1st- 3rd March 2022 the Centre for Tropical Medicine and Global Health will be hosting a demo event to showcase holographic meeting equipment and assess whether this technology offers an advantageous solution to topical issues such as hybrid meetings and international travel whilst also providing opportunities to enhance international communication.

Potentially life-saving treatment is safe to use for babies with neonatal sepsis

KWTRP

Results from a clinical trial completed in Kenya have determined that a safe dose of the antibiotic, fosfomycin, can be used to treat babies with neonatal sepsis. This is a significant development, as there are very few antibiotics specifically licensed to treat multidrug-resistant infections in babies. This research was lead by Dr Christina Obiero and Professor Jay Berkley.

Study finds steady increase in WHO-validated artemisinin resistance markers in Asia

MORU

From 2002-2018, there has been a steady increase in the places and proportion of infected people reporting validated kelch13 (K13) artemisinin resistance markers, according to a study in The Lancet Microbe. This increase in artemisinin resistance threatens efforts to eliminate malaria in Asia by 2030 — and control efforts in other endemic regions. The authors say that more consistent data collection, over longer time periods in the same areas, and rapid sharing of data are needed to map the spread of resistance and better inform policy decisions.

Global Research on AntiMicrobial resistance (GRAM) project

MORU OCGHR

Antimicrobial resistance (AMR) is responsible for at least 1.27 million deaths per year — with over 97,000 deaths in 2019 in SE Asia alone, according to a study published in The Lancet by the Global Research on AntiMicrobial resistance (GRAM) project, who urged urgent action from policymakers and health communities to avoid further preventable deaths.

Cross-species vaccination by Professor George Warimwe

Awards & Appointments KWTRP Video

Royal Society 2021 Africa Prize lecture from Professor George Warimwe. More than 70% of emerging infectious diseases (including viruses) are zoonotic, meaning they are acquired from animals, with some causing serious illness and death in humans as well as the animal host. But, what if we could immunise both humans and animals with the same vaccine?

RECOVERY trial team members appointed MBEs

Awards & Appointments General

Two RECOVERY Trial team members have been recognised in the New Year Honours list 2022. RECOVERY Trial coordinator, Professor Richard Haynes, has been appointed Member of the Order of the British Empire (MBE) for services to Global Health, and Senior Clinical Trial Manager, Lucy Fletcher, has been appointed MBE for services to Clinical Trials. The New Year Honours list recognises outstanding achievements by a wide range of extraordinary people from across the United Kingdom. People are awarded honours for achievements in their field of work (including health, education, science and technology), as well as for making a difference to their community.

Susie, Phaik Yeong, Richard and Paul among new full Oxford professors!

Awards & Appointments COMRU MORU OCGHR

In the 2021 Oxford Recognition of Distinction round, four MORU colleagues were awarded Full Professor title.

RECOVERY Trial launches in South Africa

OCGHR

The world’s largest clinical trial investigating treatments for COVID-19 has now launched in South Africa, with the first patient recruited today. This is the fifth country to take part in RECOVERY, joining Nepal, Indonesia, Vietnam, and the United Kingdom.

RECOVERY Trial wins ‘Oscar of Higher Education’ for STEM Research Project of the year

Awards & Appointments OCGHR

The RECOVERY Trial has been awarded the 2021 Times Higher Education (THE) Award in the ‘Research Project of the Year: STEM’ category.

All-nighter: staying up to fight malaria

MORU SMRU

Featured in Nature, Victor Chaumeau collects mosquitoes in Myanmar to better understand how to control malaria.

Antibiotic accountability: how countries and companies perform

MORU OCGHR

Patients in north Africa and the Middle East are using antibiotics in sharply rising quantities far beyond the global average, raising concerns over the escalating risks of resistance to medicines to treat bacterial infections. Estimated antibiotic consumption for 204 countries between 2000 and 2018 shows a 46 per cent increase in global antibiotic usage, with a surge in nations including India and Vietnam.

New! A learning framework about antimicrobial resistance for children and young people

KWTRP MORU OUCRU Public Engagement

A downloadable resource for educators, health & research professionals to help develop young peoples’ understanding of AMR and positive actions they can take to mitigate it.

Paul Newton named ASTMH Distinguished International Fellow

Awards & Appointments OCGHR

Professor Paul Newton was announced new Distinguished International Fellow at the ASTMH Annual Meeting Awards Ceremony on the 17th November. This distinction formally recognizes individuals who have made eminent contributions to a particular aspect of tropical medicine or hygiene.

Overusing antibiotics? Find out with Antibiotic Footprint Calculator

MORU

To mark WHO World Antimicrobial Awareness Week, 18-24 Nov 2021, and help reduce the overuse of antibiotics, MORU researchers have released a new, easy to use online tool – Antibiotic Footprint Calculator – that could make an important contribution in the fight against antimicrobial resistance (AMR), one of the world’s most significant emerging threats to public health.

The global burden of Plasmodium vivax malaria is obscure and insidious

Public Engagement

Until recently, Plasmodium falciparum dominated the malaria research landscape, and Plasmodium vivax infection was considered benign and inconsequential. We now know that this is not true: if not properly diagnosed and treated, P. vivax can lead to life-threatening syndromes and death. Professor Kevin Baird from EOCRU in Jakarta, Indonesia talks to OutBreak News Today

GRAM study provides the first longitudinal estimates of global antibiotic consumption in 204 countries from 2000 to 2018

MORU OCGHR

Global antibiotic consumption rates increased by 46 percent in the last two decades, according to the first study to provide longitudinal estimates for human antibiotic consumption covering 204 countries from 2000 to 2018, published in Lancet Planetary Health by the Global Research on Antimicrobial Resistance (GRAM) Project.

COVID-19 research at OUCRU

EOCRU OUCRU OUCRU-Nepal

Despite unprecedented disruptions caused globally by SARS-Cov-2, OUCRU has responded remarkably and addressed almost every important aspect of the pandemic, from its societal impact to viral genomic surveillance and COVID-19 therapy

Large-scale systematic review identifies research gaps in scrub typhus

EOCRU OCGHR OUCRU

A new, extensive systematic review has identified significant research gaps in the treatment of scrub typhus which could be improved by developing a database for individual participant data (IPD) to enable more detailed analyses to address important knowledge gaps such as the optimum dosing for children and to improve patient outcomes.

Tamoxifen repurposing study shows no benefit in treating deadly fungal meningitis

OUCRU

Hopes that tamoxifen could improve survival for a deadly form of fungal meningitis have been dashed by the results of a clinical trial conducted by University of Oxford researchers and published today in eLife.

Load More